ESR1 and cancer: In ER+ cancer models, both genetic and pharmacological inhibition of FASN, hypersensitizes ERα to estrogen dependent transactivation, inducing estrogen receptor element (ERE) transcriptional activity and MAPK-ERK signaling63.